{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:13:00Z","timestamp":1786374780267,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.2459\/jcm.0b013e32833dadc3","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T08:56:31Z","timestamp":1283331391000},"page":"858-860","source":"Crossref","is-referenced-by-count":4,"title":["What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?"],"prefix":"10.2459","volume":"11","author":[{"given":"Mohamed H","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210207","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.0954-6820.1968.tb10508.x","article-title":"Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia","volume":"183","author":"Carlson","year":"1968","journal-title":"Acta Med Scand"},{"key":"R2-14-20210207","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5414\/CPP45448","article-title":"Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation","volume":"45","author":"Menon","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R3-14-20210207","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/BOR.0b013e328032781a","article-title":"New insights into renal transport of urate","volume":"19","author":"Anzai","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"R4-14-20210207","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0002-9343(92)90689-9","article-title":"Hepatotoxicity associated with sustained-release niacin","volume":"93","author":"Dalton","year":"1992","journal-title":"Am J Med"},{"key":"R5-14-20210207","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jama.1990.03450060069031","article-title":"Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus","volume":"264","author":"Garg","year":"1990","journal-title":"JAMA"},{"key":"R6-14-20210207","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1476-5381.2009.00349.x","article-title":"Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia","volume":"158","author":"Vosper","year":"2009","journal-title":"Br J Pharmacol"},{"key":"R7-14-20210207","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"R8-14-20210207","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"R9-14-20210207","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2006.12.032","article-title":"Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits","volume":"124","author":"Zhao","year":"2008","journal-title":"Int J Cardiol"},{"key":"R10-14-20210207","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"R11-14-20210207","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2147\/VHRM.S4502","article-title":"Review of extended-release niacin\/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia","volume":"5","author":"Parhofer","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"R12-14-20210207","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"R13-14-20210207","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R14-14-20210207","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"R15-14-20210207","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"R16-14-20210207","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"R17-14-20210207","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R18-14-20210207","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jacc.2009.06.036","article-title":"Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study","volume":"54","author":"Lee","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R19-14-20210207","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1074248410361337","article-title":"Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease","volume":"15","author":"Duggal","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R20-14-20210207","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.108.836346","article-title":"Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy","volume":"121","author":"Sorrentino","year":"2010","journal-title":"Circulation"},{"key":"R21-14-20210207","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/dia.2007.0289","article-title":"Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream?","volume":"10","author":"Ahmed","year":"2008","journal-title":"Diabetes Technol Ther"},{"key":"R22-14-20210207","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc09-0738","article-title":"Statin therapy and risk of developing type 2 diabetes: a meta-analysis","volume":"32","author":"Rajpathak","year":"2009","journal-title":"Diabetes Care"},{"key":"R23-14-20210207","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2008-0222","article-title":"Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline","volume":"93","author":"Rosenzweig","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-14-20210207","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ahj.2007.01.003","article-title":"Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome","volume":"153","author":"Liu","year":"2007","journal-title":"Am Heart J"},{"key":"R25-14-20210207","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.amjcard.2007.03.103","article-title":"Ten-year cardiovascular disease risk of metabolic syndrome without central obesity in middle-aged chinese","volume":"100","author":"Zhao","year":"2007","journal-title":"Am J Cardiol"},{"key":"R26-14-20210207","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/met.2009.0074","article-title":"The effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin","volume":"8","author":"Libby","year":"2010","journal-title":"Metab Syndr Relat Disord"}],"container-title":["Journal of Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01244665-201011000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:16:47Z","timestamp":1786371407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01244665-201011000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2459\/jcm.0b013e32833dadc3","relation":{},"ISSN":["1558-2027"],"issn-type":[{"value":"1558-2027","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}